Table 2 Clinical trials using anti-platelet and anti-coagulation therapy
From: Platelets, coagulation and fibrinolysis in breast cancer progression
Drug | Target | Study description | Percentage of patients with breast cancer | Results | Breast cancer-specific results | Reference |
|---|---|---|---|---|---|---|
Aspirin | Platelets | Prospective observational study | 100% | Decreased distant recurrence and mortality | 43% risk reduction in distant recurrence and 74% risk reduction in mortality | [41] |
Benoral | Platelets | Double-blind | 100% | No survival benefit | Â | [87] |
Dalteparin | Coagulation | Randomized clinical trial in advanced-stage III and IV solid tumors | 17% | No survival benefit with advanced malignancy Improved survival in subgroup of patients with better prognosis | Unknown | [80] |
| Â | Â | Randomized double-blind controlled study changed to open-labeled clinical trial | 10.8% | No survival benefit with advanced cancer | Unknown | [81] |
Nadroparin | Coagulation | Randomized clinical trial in locally advanced or metastasized solid tumors without any concomitant chemotherapy or radiation treatment | 16.5% | Improved survival (especially more pronounced in patients with estimated life expectancy of 6 months or greater) | Hazard ratio of 0.78 | [82] |
| Â | Â | Randomized clinical trial | 14% | No survival benefit | Unknown | [83] |
Warfarin | Coagulation | Double-blind randomized trial | 100% | No detectable survival benefit but decreased relative risk of venous thromboembolism by 85% | Â | [84] |